Download PDF
Pharmacopsychiatry 2003; 36(4): 143-149
DOI: 10.1055/s-2003-41199
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Prescribing for Inpatients with Schizophrenia: An International Multi-Center Comparative Study

I. Bitter1 , J. C.-Y. Chou2 , G. S. Ungvari3 , W. K. Tang3 , Z. Xiang4 , A. Iwanami5 , P. Gaszner6
  • 1Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary
  • 2Department of Psychiatry, New York University Medical Center, Bellevue Hospital Center, New York, NY, Nathan Kline Institute, Orangeburg, NY, USA;
  • 3Department of Psychiatry, the Chinese University of Hong Kong, Hong Kong, China
  • 4Mental Health Institute and Second Medical University, Shanghai, China
  • 5Department of Psychiatry, Showa University Karasuyama Hospital, Tokyo, Japan
  • 6Department of Clinical Psychopharmacology, National Institute of Psychiatry and Neurology, Budapest, Hungary
Further Information

Publication History

Received: 27.11.2001 Revised: 2.9.2002

Accepted: 16.9.2002

Publication Date:
07 August 2003 (online)

Also available at
    Permissions and Reprints

Background: This study compares prescription practices for acute inpatients with schizophrenia among six academic departments located in China, Japan, Hungary, and the U.S.

Methods: Prescription data for a sample of 429 inpatients from six academic departments were collected on a randomly chosen census day. All patients met criteria for schizophrenia according to DSM-IV and had a length of illness of at least two years.

Results: While patients at the different centers varied in their demographic and clinical characteristics, i. e., age, sex, and length of illness, a great variation in prescription patterns for antipsychotic and other psychotropic drugs among centers was observed even within the same country for all the variables studied (i. e., number and dose antipsychotics, atypical and depot antipsychotics, other psychotropic drugs, multiple antipsychotics, and daily dose) except antidepressant use. In most cases these differences persisted even after adjusting for demographic and clinical characteristics (age, sex, and length of illness) of the subjects. Antipsychotics were usually prescribed in divided daily doses in combination with one or more other psychotropic drugs, including anticholinergics, anticonvulsants, benzodiazepines, and non-benzodiazepine hypnotics. Anticholinergic use was more common with typical antipsychotics. Rates of atypical antipsychotic drug use were lowest in the Japanese center. The Japanese center had by far the highest mean daily dose of antipsychotics.

Conclusions: The results indicate that prescription patterns in different centers do not follow any specific guidelines for the treatment of schizophrenia. The results also confirm previous findings that prescribing practices for schizophrenia vary greatly among centers and countries. A common prescribing pattern found was the use of atypical antipsychotic drugs in combination with psychotropic drugs, such as anticholinergics, hypnotics, anticonvulsants, and benzodiazepines, administered in multiple daily doses.

Key words

Schizophrenia - prescription pattern - antipsychotic drugs

References

  • 1 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.) (DSO-IV). Washington DC; APA 1994
    Google Scholar
  • 2 Al-Ghamdy Y S, Qureshi N A, Abdelghadir M H, Al-Habeeb T A, Ahmad S A. Psychotropic drugs prescriptions in Al-Qassim region, Saudi Arabia.  East Mediterr Health J. 1999;  5 27-34
    PubMedGoogle Scholar
  • 3 Atkins M, Burgess A, Bottomley C, Riccio M. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications.  Psychiatr Bull. 1997;  21 224-226
    CrossrefPubMedGoogle Scholar
  • 4 Baldessarini R J, Kando J C, Centorrino F. Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay.  Am J Psychiatry. 1995;  152 1038-1044
    PubMedGoogle Scholar
  • 5 Binder R, Levy R. Extrapyramidal reactions in Asians.  Am J Psychiatry. 1981;  38 1243-1244
    PubMedGoogle Scholar
  • 6 Buchanan R W, Kreyenbuhl J, Zito J M, Lehman A. The schizophrenia PORT pharmacological treatment recommendations: Conformance and implications for symptoms and functional outcome.  Schiz Bull. 2002;  28(1) 63-73
    PubMedGoogle Scholar
  • 7 Chang W H, Lin S K, Lane H Y, Hu W H, Jann M W, Lin H N. Clozapine dosages and plasma drug concentrations.  J Formos Med Assoc. 1997;  96 599-605
    PubMedGoogle Scholar
  • 8 Clark R E, Bartels S J, Mellman T A, Peacock W J. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: Implications for state mental health policy.  Schiz Bull. 2002;  28(1) 75-84
    PubMedGoogle Scholar
  • 9 Collazo Y, Tam R, Sramek J, Herrera J. Neuroleptic dosing in Hispanic and Asian Inpatients with schizophrenia.  Mt Sinai J Med. 1996;  63 310-313
    PubMedGoogle Scholar
  • 10 Covell N H, Jackson C T, Evans A C, Essock S M. Antipsychotic prescribing practices in Connecticut’s public mental health system: Rates of changing medications and prescribing styles.  Schiz Bull. 2002;  28(1) 17-29
    PubMedGoogle Scholar
  • 11 Dollfus S, van Os J, Petit M. Do we need a European consesus on the use of antipsychotic medication.  Eur Psychiatry. 1996;  11 400-402
    CrossrefPubMedGoogle Scholar
  • 12 Essock S M. Editor’s introduction: Antipsychotic prescribing practices.  Schiz Bull. 2002;  28(1) 1-4
    PubMedGoogle Scholar
  • 13 Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service.  Eur Psychiatry. 2000;  15 220-226
    CrossrefPubMedGoogle Scholar
  • 14 Galletly C A. Antipsychotic drug doses in a schizophrenia inpatient unit.  Aust N Z J Psychiatry. 1992;  26 574-576
    PubMedGoogle Scholar
  • 15 IMS Health: Sergeant Database. 2000
    Google Scholar
  • 16 Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia.  Psychiatry Clin Neurosci. 1999;  53 Suppl S35-40
    PubMedGoogle Scholar
  • 17 Jeffreys S E, Harvey C A, McNaught A S, Quayle A S, King M B, Bird A S. The Hampstead Schizophrenia Survey 1991. I: Prevalence and service use comparisons in an inner London health authority, 1986-1991.  Br J Psychiatry. 1997;  170 301-306
    PubMedGoogle Scholar
  • 18 Jin Z. Effect of an open-door policy combined with a structured activity programme on the residual symptoms of schizophrenic in-patients. A six-month randomised controlled trial in Yanbian, Jilin. Br J Psychiatry Suppl 1994: 52-57
    Google Scholar
  • 19 Johnson D A. Observations on the dose regime of fluphenazine decanoate in maintenance therapy of schizophrenia.  Br J Psychiatry. 1975;  126 457-461
    PubMedGoogle Scholar
  • 20 Johnson D A, Wright N F. Drug prescribing for schizophrenic out-patients on depot injections. Repeat surveys over 18 years.  Br J Psychiatry. 1990;  156 827-834
    PubMedGoogle Scholar
  • 21 Kane J M. Schizophrenia.  N Engl J Med. 1996;  334 34-41
    CrossrefPubMedGoogle Scholar
  • 22 Lane H Y, Chiu W C, Chou J CY, Wu S T, Su M H, Chang W H. Risperidone in acutely exacerbated schizophrenia: Dosing strategies and plasma levels.  Journal of Clinical Psychiatry. 2000;  61 209-214
    PubMedGoogle Scholar
  • 23 Lin K, Finder E. Neuroleptic dosage for Asians.  Am J Psychiatry. 1983;  140 490-491
    PubMedGoogle Scholar
  • 24 Lin K M, Matsuda A, Nuccio I. Neuroleptic dosage in psychiatric outpatients.  Psychiatr Serv. 1996;  47 536
    PubMedGoogle Scholar
  • 25 Lin K M, Poland R E, Nuccio I, Matsuda K, Hathuc N, Su T P, Fu P. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients.  Am J Psych. 1989;  146 1307-1311
    PubMedGoogle Scholar
  • 26 Lindstrom E, Widerlov B, von Knorring L. Antipsychotic drug - a study of the prescription pattern in a total sample of patients with a schizophrenic syndrome in one catchment area in the county of Uppland, Sweden, in 1991.  Int Clin Psychopharmacol. 1996;  11 241-246
    PubMedGoogle Scholar
  • 27 Martin B C, Miller L S, Kotzan J A. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990 s: current trends and five year time series forecasts.  Schizophr Res. 2001;  47 281-292
    CrossrefPubMedGoogle Scholar
  • 28 Matsuda K T, Cho M C, Lin K M, Smith M W, Young A S, Adams J A. Clozapine dosage, serum levels, efficacy, and side-effect profiles: A comparison of Korean-American and Caucasian patients.  Psychopharmacol Bull. 1996;  32 (2) 253-357
    PubMedGoogle Scholar
  • 29 Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing.  Br J Psychiatry. 1987;  150 501-504
    CrossrefPubMedGoogle Scholar
  • 30 Mullen R, Caan A W, Smith S. Perception of equivalent doses of neuroleptic drugs.  Psychiatr Bull. 1994;  18 335-337
    PubMedGoogle Scholar
  • 31 Okuma T. Differential sensitivity to the effects of psychotropic drugs: psychotics vs normals; Asian vs Western populations.  Folia Psychiatr Neurol Jpn. 1981;  35 79-82
    PubMedGoogle Scholar
  • 32 Peralta V, Cuesta M J, Caro F, Martinez-Larrea A. Neuroleptic dose and schizophrenic symptoms. A survey of prescribing practices.  Acta Psychiatr Scand. 1994;  90 354-357
    PubMedGoogle Scholar
  • 33 Remington G J, Prendergast P, Bezchlibnyk-Butler K Z. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.  Can J Psychiatry. 1997;  42 53-57
    PubMedGoogle Scholar
  • 34 Rey M J, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.  Int Clin Psychopharmacol. 1989;  4 95-104
    PubMedGoogle Scholar
  • 35 Rosenblatt R, Tang S. Do Oriental psychiatric patients receive different dosages of psychotropic medication when compared with Occidentals?.  Can J Psychiatry. 1987;  32 270-274
    PubMedGoogle Scholar
  • 36 Ruiz S, Chu P, Sramek J, Rotavu E, Herrera J. Neuroleptic dosing in Asian and Hispanic outpatients with schizophrenia.  Mt Sinai J Med. 1996;  63 306-309
    PubMedGoogle Scholar
  • 37 Sramek J J, Sayles M A, Simpson G M. Neuroleptic dosage for Asians: a failure to replicate.  Am J Psychiatry. 1986;  143 535-536
    PubMedGoogle Scholar
  • 38 Taylor R, McConnell D, McConnell H, Abel K, Kerwin R. The Bethlem & Maudsley NHS Trust 1999 Prescribing Guidelines. 5th edition London; Martin Dunitz 1999: p. 35
    Google Scholar
  • 39 Volavka J, Cooper T B, Czobor P, Lindenmayer J P, Citrome L L, Mohr P ,. et al . High-dose treatment with haloperidol: the effect of dose reduction.  J Clin Psychopharmacol. 2000;  20 252-256
    CrossrefPubMedGoogle Scholar
  • 40 Weissman E M. Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York Metropolitan Region.  Schiz Bull. 2002;  28(1) 31-42
    PubMedGoogle Scholar
  • 41 Wilson W H, Ban T A, Guy W. Pharmacotherapy of chronic hospitalized schizophrenics: prescription practices.  Neuropsychobiology. 1985;  14 75-82
    PubMedGoogle Scholar
  • 42 Zhang-Wong J, Beiser M, Zipursky R B, Bean G. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol.  Psychiatry Research. 1998;  81 33-339
    PubMedGoogle Scholar
  • 43 Zito J M, Craig T J, Wanderling J, Siegel C. Pharmaco-epidemiology in 136 hospitalized schizophrenic patients.  Am J Psychiatry. 1987;  144 778-782
    PubMedGoogle Scholar
  • 44 Zito J M, Safer D J, dosReis S, Gardner J F, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers.  JAMA. 2000;  283 1025-1030
    CrossrefPubMedGoogle Scholar

Istvan Bitter, M.D., Ph. D.

Area Medical Center Vienna

Eli Lilly Regional Operations GmbH

Barichgasse 40-42

1030 Wien

Austria (since November 2000)

      >